MicroPort CRM Launches MicroPort Academy CRM, an Education Website Dedicated to Healthcare Professionals and Designed by Experts in Cardiac Pacing
16.2.2021 12:00:00 EET | Business Wire | Press release
MicroPort CRM, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM. The website is dedicated to Healthcare Professionals who want to enhance their knowledge about cardiac pacing therapy and the functionality of MicroPort CRM products. It was developed in collaboration with Stimuprat Editions, and designed by world-renowned experts in cardiac pacing.
MicroPort Academy CRM provides personalized and interactive training plans, ranging from diagnosis of ECG tracings to techniques of pacemaker implantation, programming simulation and troubleshooting. The site is open to health care professionals worldwide, and is aimed at both beginners and experienced people in cardiac rhythm management.
“Providing additional training to healthcare professionals to support them in better understanding and use of our products has always been part of our mission”, said Benoît Clinchamps, President of MicroPort CRM. “Our goal is to provide the highest quality training and ensure it is accessible to everyone, all over the world. To launch this website as part of our mission, we relied on electrophysiologists who are not only experts, but who are also guided by their passion to share their experience and knowledge.”
Prof. Pierre Bordachar, Electrophysiologist from University Hospital of Bordeaux and Medical Advisor at Stimuprat Editions, stated, “There are no better trainings than those based on real cases. This is why we have paid particular attention to building courses around real world situations, illustrated by numerous ECG tracings, videos, and programming simulations. I have no doubt that MicroPort Academy CRM brings a unique experience for cardiac pacing online training.”
MicroPort Academy CRM will continue to be enriched with new modules, and to reflect both the evolution of practices and those of products. Cardiac Rhythm Management is an area where innovative solutions and technologies are emerging at a rapid pace, and where distance digital training brings all the power of their flexibility and efficiency.
For more information, please visit www.microportacademycrm.com
About MicroPort CRM
MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), whose world headquarters are in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic.
For more information, please refer to www.microport.com and www.microportacademycrm.com
About Stimuprat Editions
Stimuprat Editions, created by experts in the field of cardiology training, has been developing innovative and practical educational content for many years, allowing in-depth and unique learning experience.
Stimuprat Editions specializes in publishing books and designing digital training courses in cardiology for healthcare professionals. It offers free access on www.cardiocases.com, the largest collection of clinical cases and tracings in cardiac rhythmology, and designs training and simulation platforms on implantable device therapies for the biomedical industry.
Its unique expertise makes it the benchmark for training in the field of "Cardiac Rhythm Management".
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005513/en/
Contact information
Joël Courville – MicroPort CRM
VP Strategy and Corporate Affairs
joel.courville@crm.microport.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom